natgillin/translations-raw huggingface dataset:
In this study, mean (SD) terminal half-life was 74 (SD 27) hours. 
V tej študiji je bil povprečni terminalni razpolovni čas 74 ur (standardni odklon 27 ur).
If the haemoglobin continues to increase, the dose should be reduced by approximately 25%. 
Če se hemoglobin še naprej zvišuje, morate odmerek zmanjšati za približno 25 %.
One of the main side effects of chemotherapy is that it stops the bone marrow producing enough blood cells. 
Eden glavnih neželenih učinkov kemoterapije je, da prepreči nastajanje zadostnega števila krvnih celic v kostnem mozgu.
If signs and symptoms suggestive of these reactions appear, Aranesp should be withdrawn immediately and an alternative treatment considered. 
Če se pojavijo znaki ali simptomi, ki kažejo na takšne reakcije, je treba zdravilo Aranesp nemudoma prenehati uporabljati in razmisliti o drugačnem zdravljenju.
Two of the studies recruited patients who were being treated with chemotherapy. 
Dve sta zajeli bolnike, zdravljene s kemoterapijo.
In the once every three weeks group, 72% of patients required dose reductions. 
V skupini enkrat na tri tedne je zmanjšanje odmerka potrebovalo 72 % bolnikov, v skupini enkrat na teden pa 75 % bolnikov.
For instructions on use of the pre-filled pen, please read the section at the end of this leaflet. 
Navodila za uporabo napolnjenega injekcijskega peresnika preberite v poglavju na koncu tega navodila.
This leaflet was last revised in 
Navodilo je bilo nazadnje revidirano dne.
Aranesp has no or negligible influence on the ability to drive and use machines. 
Zdravilo Aranesp nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Erythropoietin is produced in your kidneys and encourages your bone marrow to produce more red blood cells. 
Eritropoetin nastaja v ledvicah in spodbuja kostni mozeg, da tvori več rdečih krvnih celic.
F Stretch or pinch your injection site to create a firm surface. 
F Raztegnite ali stisnite mesto injiciranja, da boste ustvarili trdno površino.
Your doctor will take regular blood samples to measure how your anaemia is responding and may adjust your dose as necessary. 
Zdravnik vam bo redno jemal kri za meritve, ki bodo pokazale, kako dobro se anemija odziva, in bo lahko odmerek prilagodil, kot bo potrebno.
If you notice a spot of blood you may gently dab it away with a cotton ball or tissue. 
Če opazite kapljico krvi, jo lahko previdno popivnate s koščkom vate ali papirnatim robčkom.
Identified adverse reactions associated with Aranesp are hypertension, stroke, thromboembolic events, convulsions, allergic reactions, rash/erythema and pure red cell aplasia (PRCA); see section 4.4. 
Med ugotovljenimi neželenimi učinki, povezanimi z zdravilom Aranesp, so hipertenzija, možganska kap, trombembolični dogodki, konvulzije, alergijske reakcije, izpuščaj/eritem in čista aplazija rdečih celic (PRCA); glejte poglavje 4.4.
The safety and effectiveness of once every three weeks dosing of Aranesp therapy in reducing the requirement for red blood cell transfusions in patients undergoing chemotherapy was assessed in a randomised, double-blind, multinational study. 
Varnost in učinkovitost zdravljenja z zdravilom Aranesp enkrat na tri tedne za zmanjšanje potrebe po transfuzijah eritrocitov so pri bolnikih na kemoterapiji raziskali v randomizirani, dvojno slepi mednarodni študiji.
The reported risk of thrombotic vascular events (TVEs) should be carefully weighed against the benefits to be derived from treatment with darbepoetin alfa particularly in patients with pre-existing risk factors for TVE, including obesity and prior history of TVEs (e.g., deep venous thrombosis, pulmonary embolism, and cerebral vascular accident). 
Poročano tveganje za trombotične žilne dogodke (TVE - Thrombotic Vascular Events) je treba skrbno pretehtati glede na pričakovano korist zdravljenja z darbepoetinom alfa, predvsem pri bolnikih z obstoječimi dejavniki tveganja za TVE, vključno z debelostjo in TVE v anamnezi (npr. globoka venska tromboza, pljučna embolija in cerebrovaskularni dogodki).
Patients starting dialysis during treatment with Aranesp should be closely monitored for adequate control of their haemoglobin. 
Bolnike, ki med zdravljenjem z zdravilom Aranesp začnejo z dializo, je treba skrbno nadzirati glede ustrezne urejenosti hemoglobina.
Do not use the pre-filled pen if any part appears cracked or broken. 
Ne uporabite napolnjenega injekcijskega peresnika, če se kateri koli del zdi zdrobljen ali zlomljen.
Instructions for use: Guide to parts 
Navodilo za uporabo: Sestavni deli
Your normal dialysis routine will not affect the ability of Aranesp to treat your anaemia. 
Vaše običajno dializno zdravljenje ne bo vplivalo na učinkovitost zdravila Aranesp pri zdravljenju anemije.
SJS/TEN can appear initially as reddish target-like spots or circular patches often with central blisters on the trunk. 
SJS/TEN se lahko sprva pojavita kot rdečkaste, tarčam podobne kožne spremembe ali krožne lehe, pogosto z osrednjim mehurjem na trupu.
When changing the route of administration the same dose must be used and the haemoglobin monitored every one or two weeks so that the appropriate dose adjustments can be made to keep the haemoglobin at the desired level. 
Če spremenite pot uporabe, morate uporabiti isti odmerek, hemoglobin pa kontrolirati na en ali dva tedna, da boste odmerek lahko prilagajali za ohranitev želene ravni hemoglobina.
• Aranesp is given as an injection into the tissue just under the skin (subcutaneous injection). 
• Zdravilo Aranesp se daje kot injekcija v tkivo tik pod kožo (subkutano injiciranje).
Your doctor has given you Aranesp (an anti-anaemic) to treat your anaemia. 
Zdravnik vam je predpisal zdravilo Aranesp (zdravilo proti slabokrvnosti) za zdravljenje anemije.
If the patient has developed a severe cutaneous skin reaction such as SJS or TEN due to the use of Aranesp, treatment with Aranesp must not be restarted in this patient at any time. 
Če se bolniku zaradi uporabe zdravila Aranesp pojavi huda kožna reakcija, na primer SJS ali TEN, se takšnemu bolniku ne sme nikoli več uvesti zdravila Aranesp.
Push down 
Pritisnite dol
In an European observational registry study which enrolled 319 paediatric patients with chronic kidney disease (13 (4.1%) patients < 1 year of age, 83 (26.0%) patients 1-< 6 years of age, 90 (28.2%) patients 6-< 12 years of age, and 133 (41.7%) patients ≥ 12 years of age) receiving darbepoetin alfa, mean haemoglobin concentrations ranging between 11.3 and 11.5 g/dL and mean weight-adjusted darbepoetin alfa doses remained relatively constant (between 2.31 mcg/kg month and 2.67 mcg/kg month) over the study period for the entire study population. 
V evropski opazovalni registrski študiji, ki je zajela 319 pediatričnih bolnikov s kronično boleznijo ledvic (13 (4,1 %) bolnikov, starih < 1 leto, 83 (26,0 %) bolnikov, starih 1 - < 6 let, 90 (28,2 %) bolnikov, starih 6 - < 12 let, in 133 (41,7 %) bolnikov, starih ≥ 12 let) zdravljenih z darbepoetinom alfa, sta med obdobjem študije ostala povprečna koncentracija hemoglobina v razponu od 113 do 115 g/l in povprečni na telesno maso prilagojeni odmerek darbepoetina alfa (od 2,31 µg/kg na mesec do 2,67 µg/kg na mesec) razmeroma stalna v celotni študijski populaciji.
The longer terminal half-life of darbepoetin alfa administered subcutaneously compared to intravenously is due to subcutaneous absorption kinetics. 
Daljši terminalni razpolovni čas subkutano apliciranega darbepoetina alfa v primerjavi z intravensko apliciranim je posledica kinetike subkutane absorpcije.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.375 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 0,375 ml
Due to intra-patient variability, occasional individual haemoglobin values for a patient above and below the desired haemoglobin level may be observed. 
Zaradi variabilnosti med bolniki se lahko občasno pri posameznem bolniku pojavijo vrednosti hemoglobina, ki so višje ali nižje od želene koncentracije.
Aranesp may be administered subcutaneously by the patient or a carer after being trained by a doctor, nurse or pharmacist. 
Zdravilo Aranesp si lahko daje podkožno bolnik sam ali oseba, ki zanj skrbi, potem ko so ju za to usposobili zdravnik, medicinska sestra ali farmacevt.
Haemoglobin concentrations were corrected to ≥ 10 g/dL in > 98% (p < 0.001) of paediatric patients administered darbepoetin alfa once weekly and 84% (p = 0.293) once every two weeks. 
Koncentracija hemoglobina se je popravila na ≥ 100 g/l pri > 98 % (p < 0,001) pediatričnih bolnikov, ki so dobivali darbepoetin alfa vsak teden, in pri 84 % (p = 0,293) tistih, ki so ga dobivali vsaka dva tedna.
Manufacturer Amgen NV Telecomlaan 5-7 1831 Diegem Belgium 
Proizvajalec Amgen NV Telecomlaan 5-7 1831 Diegem Belgija
Characteristics (Revision 2, September 2009), frequency of adverse reactions identified in the post-marketing setting was determined using the “Rule of three”. 
Product Characteristics (revizija 2, september 2009) je bila pogostnost neželenih učinkov, prepoznanih v obdobju trženja zdravila, določena z uporabo “pravila trojke”.
It is unknown whether Aranesp is excreted in human milk. 
Ni znano, ali se zdravilo Aranesp pri človeku izloča v materino mleko.
Aranesp 25, 40, 60, 100, 200, 300 micrograms solution for injection in vial Aranesp is administered either subcutaneously or intravenously as described in the posology. 
Aranesp 25, 40, 60, 100, 200, 300 mikrogramov raztopina za injiciranje v viali Zdravilo Aranesp se uporablja subkutano ali intravensko, kot je opisano v poglavju Odmerjanje.
Carefully lift the pre-filled pen straight up out of the carton. 
Previdno dvignite napolnjeni injekcijski peresnik naravnost iz škatle.
1 Adverse reactions identified in the post-marketing environment. 
1 Neželeni učinki prepoznani v obdobju trženja zdravila.
• Store the pre-filled pen in the refrigerator (2ºC - 8ºC). 
• Napolnjen injekcijski peresnik shranjujte v hladilniku (2 °C - 8 °C).
Patients should be monitored closely to ensure that the lowest approved effective dose of Aranesp is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dL (7.5 mmol/L). 
Bolnike je treba skrbno nadzirati, da bi zagotovili uporabo najmanjšega odobrenega učinkovitega odmerka zdravila Aranesp, potrebnega za ustrezno obvladanje simptomov anemije ob hkratnem vzdrževanju koncentracije hemoglobina pod ali na 120 g/l (7,5 mmol/l).
A paradoxical decrease in haemoglobin and development of severe anaemia associated with low reticulocyte counts should prompt to discontinue treatment with epoetin and perform anti-erythropoietin antibody testing. 
V primeru paradoksnega znižanja hemoglobina in nastanka hude anemije, ki jo spremlja majhno število retikulocitov, je treba zdravljenje z epoetinom prekiniti in opraviti testiranje antieritropoetinskih protiteles.
PHARMACEUTICAL FORM AND CONTENTS 1 single use vial 
FARMACEVTSKA OBLIKA IN VSEBINA 1 viala za enkratno uporabo
Caution should be exercised with escalation of Aranesp doses in patients with chronic renal failure, since high cumulative epoetin doses may be associated with an increased risk of mortality, serious cardiovascular and cerebrovascular events. 
Bolnikom s kronično odpovedjo ledvic je treba odmerke zdravila Aranesp povečevati previdno, ker so visoki kumulativni odmerki epoetina lahko povezani s povečanim tveganjem za umrljivost ter resne kardiovaskularne in cerebrovaskularne dogodke.
Dose changes in the maintenance phase of treatment should not be made more frequently than every two weeks. 
Med vzdrževalnim zdravljenjem odmerka ne smete spreminjati pogosteje kot na dva tedna.
There is therefore consistent evidence to suggest that there may be significant harm to patients with cancer who are treated with recombinant human erythropoietin. 
Obstajajo konsistentni dokazi, da lahko bolnikom z rakom zdravljenje z rekombinantnim humanim eritropoetinom škoduje.
The following side effects have been experienced by some patients taking Aranesp: 
Naslednji neželeni učinki so se pojavili pri nekaterih bolnikih, ki so dobivali zdravilo Aranesp:
These antibodies have been shown to cross-react with all erythropoietic proteins, and patients suspected or confirmed to have neutralising antibodies to erythropoietin should not be switched to Aranesp (see section 4.8). 
Ugotovljeno je, da ta protitelesa navzkrižno reagirajo z vsemi eritropoetičnimi beljakovinami; bolnikov, pri katerih obstaja sum ali pri katerih je potrjeno, da imajo nevtralizirajoča protitelesa proti eritropoetinu, ne smete prevesti na zdravilo Aranesp (glejte poglavje 4.8).
Epoetins are growth factors that primarily stimulate red blood cell production. 
Epoetini so rastni dejavniki, ki stimulirajo predvsem nastajanje rdečih krvnih celic.
These parameters were consistent with dose linear pharmacokinetics over a wide dose range (0.5 to 8 mcg/kg weekly and 3 to 9 mcg/kg every two weeks). 
Ti parametri se skladajo s farmakokinetiko, linearno povezano z odmerkom, v širokem odmernem območju (od 0,5 do 8 µg/kg na teden in od 3 do 9 µg/kg na dva tedna).
If after a dose reduction, haemoglobin continues to increase, the dose should be temporarily withheld until the haemoglobin begins to decrease, at which point therapy should be reinitiated at approximately 25% lower than the previous dose. 
Če se hemoglobin po zmanjšanju odmerka še naprej zvišuje, uporabo začasno prekinite, dokler se hemoglobin ne začne zniževati; potem terapijo znova uvedite z odmerkom, približno 25 % manjšim od prejšnjega.
When substituting Aranesp for r-HuEPO the haemoglobin should be monitored every one or two weeks and the same route of administration should be used. 
Pri zamenjavi r-HuEPO z zdravilom Aranesp je treba hemoglobin kontrolirati na en ali dva tedna in uporabiti isto pot aplikacije.
Your doctor will tell you how much and how often you must take Aranesp in order to maintain a haemoglobin level between 10 and 12 g/dL. 
Zdravnik vam bo povedal, koliko zdravila Aranesp morate uporabljati in kako pogosto, da boste koncentracijo hemoglobina ohranili med 100 in 120 g/l.
Data from 809 patients receiving Aranesp in European clinical studies were analysed to assess the dose required to maintain haemoglobin; no difference was observed between the average weekly dose administered via the intravenous or subcutaneous routes of injection. 
Za določitev odmerka, potrebnega za vzdrževanje hemoglobina, so analizirali 809 bolnikov, ki so zdravilo Aranesp dobivali v evropskih kliničnih študijah; med povprečnim tedenskim odmerkom, uporabljenim intravensko ali subkutano, niso ugotovili razlik.
Special warnings: - If you have symptoms which include unusual tiredness and a lack of energy this could mean you have pure red cell aplasia (PRCA), which has been reported in patients. 
Posebna opozorila: - Če imate simptome, med katerimi sta nenavadna utrujenost in pomanjkanje energije, to lahko pomeni, da imate čisto aplazijo rdečih celic.
The extent to which these outcomes might apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/dL, is unclear because few patients with these characteristics were included in the data reviewed. 
Ni pa jasno, v kolikšni meri bi te ugotovitve lahko veljale za uporabo rekombinantnega eritropoetina pri bolnikih z rakom, ki dobivajo kemoterapijo, če je ciljna koncentracija hemoglobina manjša od 130 g/l; analizirani podatki so namreč obsegali le malo bolnikov s takšnimi značilnostmi.
This study supports 500 mcg once every three weeks being comparable to once weekly administration with respect to the incidence of subjects receiving at least one red blood cell transfusion from week 5 to the end of treatment phase. 
Študija potrjuje, da je uporaba 500 µg enkrat na tri tedne primerljiva uporabi enkrat na teden, kar zadeva incidenco preiskovancev, ki so od 5. tedna do konca faze zdravljenja dobili vsaj eno transfuzijo eritrocitov.
In order to correct your anaemia, your initial dose will be 
Za odpravljanje anemije boste dobili začetni odmerek
If you want to stop using Aranesp, you should discuss it with your doctor first. 
Če želite prenehati uporabljati zdravilo Aranesp, se pred tem posvetujte z zdravnikom.
If you need to use the same injection site, just make sure it is not the same spot on that site you used last time. 
Če morate uporabiti enako mesto injiciranja, zagotovite, da na tem mestu ne uporabite iste točke kot pri zadnjem injiciranju.
In all paediatric CRF studies, there were no additional adverse reactions identified for paediatric patients compared to those previously reported for adult patients (see section 5.1). 
V vseh študijah pri pediatričnih bolnikih s kronično odpovedjo ledvic niso ugotovili dodatnih neželenih učinkov pri pediatričnih bolnikih v primerjavi s tistimi, ki so bili že pred tem opisani pri odraslih bolnikih (glejte poglavje 5.1).
If you want to use the same injection site, make sure it is not the same spot on the injection site you used for a previous injection. 
Če želite uporabiti isto mesto za injiciranje, se prepričajte, da ne boste injicirali na isti točki kot ste pri predhodnem injiciranju.
Name and address of the manufacturers responsible for batch release 
Ime in naslov proizvajalcev, odgovornih za sproščanje serije
For adult patients not on dialysis, 1.5 micrograms/kg once monthly may also be used as the initial dose. 
Za odrasle bolnike, ki niso na dializi, je mogoče kot začetni odmerek uporabiti tudi 1,5 mikrograma/kg enkrat na mesec.
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients (see section 4.2). 
Zdravljenje simptomatske anemije, povezane s kronično odpovedjo ledvic pri odraslih in pri pediatričnih bolnikih (glejte poglavje 4.2).
Aranesp should also be used with caution in those patients with sickle cell anaemia. 
Prav tako morate zdravilo Aranesp uporabljati previdno pri bolnikih z anemijo srpastih celic.
What Aranesp is and what it is used for What you need to know before you use Aranesp How to use Aranesp 
Kaj je zdravilo Aranesp in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Aranesp Kako uporabljati zdravilo Aranesp Možni neželeni učinki
Before you use the Aranesp SureClick pre-filled pen, read this important information: Storing your Aranesp SureClick pre-filled pens 
Pred uporabo napolnjenega injekcijskega peresnika zdravila Aranesp preberite te pomembne informacije: Shranjevanje napolnjenega injekcijskega peresnika zdravila Aranesp
The MAH shall agree the final educational material with the national competent authority where the pre-filled pen is marketed. 
Imetnik dovoljenja za promet z zdravilom se mora o končnem izobraževalnem gradivu dogovoriti s pristojnim nacionalnim organom države, v kateri se napolnjeni injekcijski peresnik trži.
How do I prepare my Aranesp injection? 
Kako pripravim injekcijo zdravila Aranesp?
Convulsions 
konvulzije
If it occurs, appropriate dose adjustment should be made as provided. 
Če se to vseeno zgodi, morate odmerek ustrezno prilagoditi.
Dosing should be titrated as necessary to maintain the haemoglobin target. 
Odmerjanje je treba prilagajati, kot je potrebno za vzdrževanje ciljne koncentracije hemoglobina.
Do not use any Aranesp that is left in the syringe. 
Ne uporabljajte preostanka zdravila Aranesp, ki je ostal v brizgi.
Caution should be exercised when prescribing Aranesp to pregnant women. 
Pri predpisovanju zdravila Aranesp nosečnicam je potrebna previdnost.
Significantly fewer patients received RBC transfusions in the epoetin alfa plus SOC arm (5.8% versus 11.4%); however, significantly more patients had thrombotic vascular events in the epoetin alfa plus SOC arm (2.8% versus 1.4%). 
Značilno manj bolnikov je prejelo transfuzije eritrocitov v skupini z epoetinom alfa in standardno oskrbo (5,8 % v primerjavi z 11,4 %); vendar pa je imelo značilno več bolnikov trombotične žilne dogodke v skupini z epoetinom alfa in standardno oskrbo (2,8 % v primerjavi z 1,4 %).
In the event of polycythaemia, Aranesp should be temporarily withheld (see section 4.2). 
V primeru policitemije je treba uporabo zdravila Aranesp prehodno prekiniti (glejte poglavje 4.2).
If Aranesp is given concomitantly with any of these treatments, blood levels of these substances should be monitored and the dosage adjusted as the haemoglobin rises. 
Če zdravilo Aranesp dajete sočasno s temi zdravili, je treba koncentracijo teh snovi v krvi kontrolirati in odmerke prilagajati, ko se koncentracija hemoglobina zvišuje.
Your doctor will check that your haemoglobin does not exceed a certain level, as high haemoglobin concentrations could put you at risk of having a problem of the heart or the blood vessels and could increase risk of myocardial infarction, stroke and death. 
Zdravnik bo preverjal, da vam koncentracija hemoglobina ne bo presegla določene vrednosti, kajti visoke koncentracije hemoglobina vas lahko izpostavijo tveganju za težave s srcem ali ožiljem in vam povečajo tveganje za srčni infarkt, možgansko kap in smrt.
If you develop a serious rash or another of these skin symptoms, stop taking Aranesp and contact your doctor or seek medical attention immediately. 
Če se vam pojavi resen izpuščaj ali kakšen drug od teh kožnih simptomov, takoj prenehajte uporabljati zdravilo Aranesp in se nemudoma posvetujte s svojim zdravnikom ali nemudoma poiščite zdravniško pomoč.
Overall survival outcome in the trials could not be satisfactorily explained by differences in the incidence of thrombosis and related complications between those given recombinant human erythropoietin and those in the control group. 
Rezultata celotnega preživetja v teh preskušanjih ni mogoče zadovoljivo pojasniti z različno incidenco tromboze in sorodnih zapletov med bolniki, ki so dobivali rekombinantni humani eritropoetin, in bolniki v kontrolni skupini.
Healthcare Providers only Remove and save the pre-filled syringe label. 
Samo za zdravstveno osebje Odstranite in shranite nalepko z napolnjene injekcijske brizge.
If clinically indicated, phlebotomy may be performed. 
Narediti je mogoče flebotomijo, če je klinično indicirana.
4 single use vials 
4 viale za enkratno uporabo
Remove the pre-filled syringe from the refrigerator. 
Vzemite napolnjeno injekcijsko brizgo iz hladilnika.
Due to its increased carbohydrate content darbepoetin alfa has a longer terminal half-life than r-HuEPO and consequently a greater in vivo activity. 
Zaradi večje vsebnosti ogljikovih hidratov je terminalni razpolovni čas darbepoetina alfa daljši kot terminalni razpolovni čas r-HuEPO, zato je njegova aktivnost in vivo večja.
Misuse of Aranesp by healthy persons may lead to an excessive increase in packed cell volume. 
Zloraba zdravila Aranesp pri zdravih osebah lahko povzroči čezmerno zvečanje hematokrita.
In case PRCA is diagnosed, therapy with Aranesp must be discontinued and patients should not be switched to another recombinant erythropoietic protein (see section 4.4). 
Če je diagnosticirana čista aplazija rdečih celic, morate zdravljenje z zdravilom Aranesp prekiniti, bolnika pa ne smete prevesti na drugo rekombinantno eritropoetično beljakovino (glejte poglavje 4.4).
Patients were randomised to receive Aranesp at 500 mcg once every three weeks or 2.25 mcg/kg once weekly. 
Bolnike so randomizirali na prejemanje zdravila Aranesp 500 µg enkrat na tri tedne ali 2,25 µg/kg enkrat na teden.
Use a new pre-filled syringe and call your doctor or healthcare provider. 
Uporabite novo napolnjeno injekcijsko brizgo in se posvetujte z zdravnikom ali zdravstvenim delavcem.
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 0.65 ml 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 0,65 ml
EPO-ANE-3010, a randomised, open-label, multicentre study was conducted in 2,098 anaemic women with metastatic breast cancer, who received first line or second line chemotherapy. 
V randomizirani, odprti, multicentrični študiji EPO-ANE-3010 je sodelovalo 2.098 slabokrvnih žensk z metastatskim rakom dojke, ki so prejemale kemoterapijo v prvi ali drugi liniji.